32 −3.2 ± 7.4 −3.0 ± 8.3 13.44 ± 3.22 1.3 ± 6.2 1.8 ± 6.1 Inter-trochanter Cortical thickness (mm) 1.43 ± 0.26 0.9 ± 5.9 0.7 ± 6.4 1.51 ± 0.29 buy EX 527 −2.3 ± 6.6 −0.8 ± 7.7 Cortical CSA (cm2) 1.38 ± 0.29 3.8 ± 7.4* 2.9 ± 8.6 1.54 ± 0.33 −1.6 ± 5.6 −0.6 ± 5.5 Total CSA (cm2) 2.38 ± 0.45 3.8 ± 8.8* 4.7 ± 9.4* 2.59 ± 0.5 −1.8 ± 5.6 −0.6 ± 4.8 Cortical perimeter (cm) 16.76 ± 1.15 0.2 ± 3.3 −0.6 ± 2.0 17.12 ± 1.18 0.6 ± 2.4 0.0 ± 2.1 Cortical vBMD (mg/cm3) 638.96 ± 48.01 −0.4 ± 2.4 −1.5 ± 2.1** 646.03 ± 44.09 −0.3 ± 2.9 −0.6 ± 2.4 Total vBMD (mg/cm3) 186.13 ± 35.97 1.1 ± 3.3 0.7 ± 4.7 196.1 ± 35.7 −1.5 ± 4.5
−1.5 ± 4.8 SM (cm3) 0.67 ± 0.18 5.0 ± 15.8 4.1 ± 11.8 0.73 ± 0.18 2.4 ± 12.0 1.8 ± 10.2 BR 19.71 ± 3.6 2.1 ± 10.2 1.8 ± 10.7 19.26 ± 4.41 4.3 ± 9.5* 2.1 ± 10.1 Femoral shaft Cortical thickness (mm) 3.71 ± 0.62 0.7 ± 5.1 2.6 ± 4.5* 3.91 ± 0.62 −0.7 ± 4.6 −1.3 ± 3.9 Cortical CSA (cm2) 2.22 ± 0.39 1.7 ± 5.2 2.7 ± 3.6* 2.35 ± 0.39 −0.6 ± 4.1 −0.5 ± 3.0 Total CSA (cm2) 2.38 ± 0.38 1.7 ± 5.0 2.5 ± 3.4* 2.5 ± 0.39 −0.5 ± 4.0 −0.1 ± 3.0
Cortical perimeter (cm) 10.27 ± 0.6 0.4 ± 3.8 −0.7 ± 2.5 10.3 ± 0.7 0.2 ± 4.3 0.5 ± 3.2 Cortical vBMD (mg/cm3) 879.65 ± 70.77 0.4 ± 2.7 0.1 ± 3.6 892.97 ± 59.03 0.3 ± 4.1 −0.9 ± 3.1 Total vBMD (mg/cm3) 461.36 ± 77.37 0.7 ± 5.1 1.1 ± 5.7 482.05 ± 74.95 −0.2 ± 5.2 −1.4 ± 4.3 SM (cm3) 0.88 ± 0.18 1.3 ± 5.9 2.7 ± 7.2 0.93 ± 0.2 https://www.selleckchem.com/products/lcz696.html −0.8 ± 5.2 0.3 ± 4.8 BR 3.67 ± 0.88 −0.4 ± 7.7 −3.3 ± 5.4* 3.39 ± 0.75 0.9 ± 6.7 1.9 ± 5.3 Data are mean ± SD QCT quantitated computed tomography, CSA cross-sectional area, vBMD volumetric bone mineral density, ASK1 SM section selleckchem modulus, BR buckling ratio * p < 0.05; ** p < 0.01 compared with baseline Effect of teriparatide on cortical thickness, cortical and total CSA, and cortical perimeter compared to placebo Comparisons of cortical thickness, CSA, and perimeter between the two groups are shown in Fig. 1. 1 Mean percent changes and 95 % confidence interval from baseline in cortical thickness (a), cortical cross-sectional area (CSA) (b), total CSA (c), and cortical perimeter (d) at 48 and 72 weeks of treatment with teriparatide and placebo.